Introduction
Biomarkers are indicators of specific biological states. Cancer biomarkers can aid in diagnosis and/or patient management by refining staging and predicting or monitoring response to treatment (1, 2) . Proteomics is particularly promising for the analysis of biological fluids and biomarker identification. The current interest in proteomics is due in part to its power to interrogate the end player encoded for in the genome, namely the proteins. Here, we discuss innovative proteomic approaches that have been successful for biomarker discovery.
Challenges of Plasma-Based Biomarker Discovery
Plasma is among the most accessible biological materials available. However, the plasma proteome is particularly challenging because of its complexity and vast dynamic range. Plasma contains several thousand proteins with concentrations ranging from as high as 20-50 mg/mL for serum albumin to femtomolar concentrations for some known biomarkers (3) . Plasma consists of vast assemblies of proteins and complexes that reflect the physiologic or pathologic state of cells, tissues, and organs, with many of the plasma proteins found in multiple forms (4) . Some forms result from alternative splicing at the RNA level, and others result from cleavages and posttranslational modifications (5) . This plethora of protein forms, combined with the vast dynamic range of concentrations, presents the greatest challenge to plasma biomarker discovery. While mass spectrometry (MS) has evolved sufficiently to detect and identify femtomoles of peptides, the dynamic range of detection is still a limiting factor for comprehensive serum profiling (6, 7) .
In order to overcome the challenge presented by the wide range of concentrations of plasma proteins, three basic strategies have been developed: (i) removal of high abundance proteins, such as albumin and immunoglobulins that interfere with the detection of less abundant proteins (8) ; (ii) fractionation of samples, by chromatographic or other means of separation, to reduce complexity prior to MS (4, 7, 9) ; and (iii) isolation of targeted groups of proteins or peptides of interest (10) (11) (12) . Using a combination of depletion of abundant proteins and extensive fractionation, together with isotopic labeling (13), our group was able to identify several cancer biomarkers in plasma other than nonspecific inflammatory and acute phase protein markers (Figure 1 ).
Extensive fractionation of intact proteins permits a more detailed investigation of the particular protein forms identified and their posttranslational modifications that may be associated with disease; a feature that is not Substantial technological advances in proteomics and related computational science have been made in the past few years. These advances overcome in part the complexity and heterogeneity of the human proteome, permitting quantitative analysis and identification of protein changes associated with tumor development. Here, we discuss some of these advances that are uncovering new cancer biomarkers that have potential to detect cancer at early and curable stages and address remaining challenges. readily achievable with protein digestion-based fractionation approaches. Figure 2 illustrates this feature, with the identification of a C-terminal fragment of insulin-like growth factor binding protein 2 (IGFBP2) separate from the intact protein. Several proteolytic enzymes have been identified that cleave IGFBPs. It has been suggested that proteolytic cleavage of IGFBPs is associated with regulation of the proliferative effects of IGFs on their target cells (14) .
Cell-Based Proteomics
Tumor cells and cancer cell lines are also valuable sources of potential cancer biomarkers. A multitude of approaches for cell protein analysis have yielded quantitative information. Here we address strategies that fall under the heading of functional proteomics.
Stable isotope labeling of amino acids in cell culture (SILAC) has become a popular approach to study the proteomes of various cell types and microorganisms and how they change in response to various conditions (15) . In a nutshell, cells are grown in culture in the presence of one amino acid, such as lysine, for which all the 12C were substituted by 13C. Incorporation of this isotopically labeled amino acid occurs in the process of cell growth, protein synthesis, and turnover. SILAC allows light and heavy proteomes to be distinguished by MS.
This approach has been used to study cancer cell spread (16) and cancer cell secretion (17) , as well as to identify therapeutic targets (18) .
More focused approaches within the category of functional proteomics aim to facilitate the analysis of complex proteomes by selecting specific protein functions of interest. This strategy, referred to as activity-based protein profiling, uses active site-directed probes to interrogate, for example, the functional state of enzyme families (19) (20) (21) . The delineation of enzyme activities selectively associated with tumor cells or tissues has the potential to yield a rich source of biomarkers and targets for cancer diagnosis and therapy. Quantitative profiling of the activity of the SH family of enzymes demonstrated that the membrane and secreted proteomes are especially enriched in enzyme activities that serve as markers of cellular phenotype (22) .
Other targeted approaches recently developed for mapping protein signaling pathways within tumors can also aid in identifying new targets for cancer therapies. The process of phosphorylation through kinase-dependent signaling pathways has relevance to cell growth and cell cycle control. The phosphorylation status of proteins can be measured using specific antiphosphoprotein antibodies arrayed in microarrays, permitting a high-throughput and multiplexing interrogation of the state of entire signaling pathways (23) . Protein pathway analysis of human rhabdomyosarcoma with this methodology revealed a strong association between activation (phosphorylation) of multiple components of the Akt/mTOR pathway and a poor disease outcome or overall survival. These findings warrant testing for Akt/mTOR pathway inhibitors as potential therapy for rhabdomyosarcoma (24) . One recently developed alternative to antibody microarrays consists of peptide microarrays that detect protein kinase activity in cell lysates by arraying substrate peptides for kinases (25) . Additionally, the monitoring of cell signaling pathways is also being performed by MS-based methods to selectively identify and quantify phosphopeptides (26) .
As with the direct study of plasma, all these approaches usually generate a list of biomarker candidates associated with a given disease state in a given study. However, further validation is required. In the case of cell line-derived candidate biomarkers, validation of the observations using patient-derived specimens is needed to assess the relevance of candidate biomarkers discovered.
Autoantibodies
A promising approach for the identification of cancer biomarkers that may be useful for early detection is the analysis of serum for autoantibodies against tumor pro- Multiple proteins, which induce autoantibodies that may constitute a panel specific for a cancer type, have been identified using two-dimensional polyacrylamide gel electrophoresis (2D-PAGE), whereby the two-dimensional separation of tumor proteins is followed by Western blotting analysis and incubation with patient sera (30) . For most antigenic proteins identified using this approach, posttranslational modifications contributed to the immune response, as has been shown for autoantibodies directed toward a carbohydrate epitope of glycosylated annexins I and II (31) . Alternatively, microarray technology has been used to monitor antigenicity of proteins produced naturally in tumor cells. Microarrays provide a high-throughput, high-sensitivity alternative to the use of Western blot analyses for tumor antigen profiling (32, 33) .
Future Directions
A useful repertoire of proteomics technologies is currently available for disease-related applications, although further technological innovations would be beneficial to increase sensitivity, reduce sample size requirements, increase throughput, and more effectively uncover various types of protein alterations, such as posttranslational modifications. One of these advances can be exemplified with the demonstration that multiple single-cell signaling events can be tracked simultaneously using flow cytometry (34) . This application of single-cell proteomics can delineate pathways directly related to cancer, providing both diagnostic and therapeutic applications.
In terms of different biological approaches that may facilitate proteomic discovery of biomarkers, mouse models of cancer have emerged as a potential source of biomarkers applicable to humans. Mouse models of cancer potentially represent an efficient means for uncovering diagnostic markers, as genetic alterations associated with human tumors can be engineered in mice. In addition, defined stages of tumor development, breeding conditions, and blood sampling can all be controlled and standardized to limit heterogeneity. Similarly, human cancer cells can be transplanted into mice, and tumor development monitored in xenotransplants. Mouse-based studies promise to elucidate a repertoire of protein changes that occur in blood and biological fluids during tumor development (35) .
The application of high-throughput procedures to the discovery of biomarkers leads to large data sets of multidimensional data and a certain percentage of false discoveries. It becomes crucial, therefore, to carefully design validation studies and to characterize, in a representative population, the sensitivity and specificity [i.e., (true positives)/(true positives + false-negatives) and (true negatives)/(true negatives + false-positives)], respectively (36), of each biomarker candidate. For a detailed discussion of biomarker validation, see Reference 37. Additionally, it is more likely that a robust predictor of the precancerous or cancerous state is a combination of markers.
